BioCentury
ARTICLE | Financial News

TCR2 seeks IPO as first program slated to enter clinic

January 4, 2019 4:19 AM UTC

Looking to bring at least one of its cell therapy programs to the clinic in 2019, TCR2 Therapeutics Inc. (Cambridge, Mass.) filed on Dec. 28 to raise $100 million in an IPO on NASDAQ.

TCR2 is developing T cell receptor fusion constructs (TRuCs), which comprise tumor antigen recognition domains fused to TCRs. The company thinks its TRuCs could have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies (see "TRuCs vs. CARs")...

BCIQ Company Profiles

TCR2 Therapeutics Inc.